Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
DE000A0HGQF5
Thu, 12.11.2020
MagForce AG
Significant treatment revenues generated for the first time, roll-out in
Europe and Germany to be continued; Approval for prostate treatment
expected in 2021
In the first six months of 2020, MagForce AG treated a significant number
of glioblastoma patients for the first time. By treating 11 patients in
Germany and six patients in Poland, the com [ … ]
Thu, 15.10.2020
MagForce AG
In its current letter to shareholders, MagForce AG reports a sustained
positive development in the number of treatments for brain tumor patients
(glioblastoma) in Europe. After the preparatory work for the
commercialization of the MagForce technology has been completed in recent
years, significant treatment revenues are expected to be generated fo [ … ]